Indole derivatives and their synthesis methods and applications

By synthesizing indole derivative antimicrobial cyclic peptides, the problem of multidrug-resistant bacterial infections has been solved, achieving highly efficient killing of Escherichia coli, Staphylococcus aureus, and Bacillus subtilis, while being low in cost and having low hemolytic toxicity.

CN118373885BActive Publication Date: 2024-11-01DEZHOU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410847069.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-06-27
Publication Date
2024-11-01
Estimated Expiration
2044-06-27

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively address the problem of multidrug-resistant bacterial infections, especially the resistance of Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, Staphylococcus aureus, and Bacillus subtilis. Polymyxins have become the last effective means, but new antibacterial drugs need to be developed.

Method used

An indole derivative antibacterial cyclic peptide with the amino acid sequence RRRWWWV was synthesized via Fmoc solid-phase synthesis. The first and last amino acids form an amide bond to form a ring, which improves antibacterial activity and stability and reduces biotoxicity.

Benefits of technology

Indole compounds exhibit significantly enhanced antibacterial activity, possessing broad-spectrum killing activity against Escherichia coli, Staphylococcus aureus, and Bacillus subtilis, with extremely low hemolytic toxicity and low cost, making them suitable for highly effective antibacterial action at low concentrations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118373885B_ABST
    Figure CN118373885B_ABST
Patent Text Reader

Abstract

The present invention relates to the technical field of heterocyclic compounds, and specifically discloses indole derivatives and synthesis methods and applications thereof, comprising an amino acid sequence of: R-R-R-W-W-W-W-V; the antibacterial cyclic peptide is obtained by cyclizing the above amino acid sequence. The indole derivative provided by the present invention is synthesized by Fmoc solid phase chemistry; the antibacterial cyclic peptide has a broad-spectrum killing activity against Escherichia coli, Bacillus subtilis, and Staphylococcus aureus at low concentrations, and the antibacterial activity is significantly improved compared to before cyclization, and has no toxic effect on mammalian red blood cells, has relatively low cost, and is highly operable.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of heterocyclic compounds, in particular to indole derivatives and synthesis methods and applications thereof. Background Art

[0002] With the widespread use of antibiotics in clinical practice, the incidence of multidrug-resistant bacteria has also increased. The most common multidrug-resistant Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii) and Gram-positive bacteria (Staphylococcus aureus and Bacillus subtilis) responsible for clinical infections have become a serious global health concern. Faced with the growing problem of drug resistance, polymyxins (such as colistin) have once again become the last resort for the treatment of drug-resistant infections, making the development of new antimicrobial agents a current research priority.

[0003] Antimicrobial peptides (AMPs) have become a promising alternative as small molecule antimicrobial agents for the treatment of antibiotic-resistant pathogens and have attracted widespread attention over the past few decades. AMPs are a class of polypeptide molecules composed of 10-40 amino acid residues with antimicrobial activity. They are encoded by host genes and are important components of the host's own immune defense system. Natural AMPs have been found in mammals, amphibians, insects, and plants. AMPs have broad-spectrum antimicrobial activity and can exert rapid and efficient antimicrobial effects in a relatively short period of time. They have strong bactericidal activity against Gram-negative bacteria, Gram-positive bacteria, fungi, and some enveloped viruses and protozoa.

[0004] To identify antimicrobial peptides from peptide libraries, researchers initially conducted experiments to screen and identify their antimicrobial activity. However, due to the lengthy, tedious, and expensive nature of these experiments, the continuous development of bioinformatics has led to the use of computational methods for screening and activity prediction, effectively overcoming the shortcomings of experimental methods. Summary of the Invention

[0005] In response to the above technical problems, the purpose of the present invention is to provide indole derivatives and their synthesis methods and applications. The present invention also provides antibacterial applications of such indole compounds, which have strong antibacterial activity, relatively low cost and low hemolytic toxicity.

[0006] In order to achieve the above object, the technical solution of the present invention is: an indole compound having a chemical structural formula I, wherein the indole compound is an anti-multidrug resistant bacterial cyclopeptide containing an amino acid sequence, the amino acid sequence of which is: RRRWWWWV; i.e., Arg-Arg-Arg-Trp-Trp-Trp-Trp-Trp-Val; also named [R3W4V].

[0007] The antibacterial cyclic peptide is obtained by forming an amide bond between the amino group and the carboxyl group of the first and last amino acids of the amino acid sequence to form a ring.

[0008] Structural formula I is:

[0009] .

[0010] The present invention compares the cationic antibacterial cyclic peptide linear peptide: RRRWWWWV. Preliminary experimental studies have found that it has good antibacterial activity. In order to improve the antibacterial activity and polypeptide stability and reduce the biological toxicity of the polypeptide, based on the excellent property of cyclic peptides that they can easily penetrate bacterial cell membranes, the amino groups and carboxyl groups of the first and last amino acids of the linear peptide form amide bonds to form a ring to synthesize a cyclic peptide.

[0011] The indole compound provided by the present invention is prepared by using the Fmoc solid-phase synthesis method: in the first step, starting from the C-terminus of the peptide segment, the first Fmoc-protected amino acid is first linked to the dichlororesin 2-CTC resin, then the Fmoc is removed, the second amino acid is linked, and all amino acids are linked in sequence. In the second step, the linked peptide segment is cleaved from the resin to obtain a mixture of peptide segments with all protections removed. In the third step, the fully protected linear peptide is reacted with the condensing agent DIC / Cl-HOBt. After the reaction is completed, water is added to precipitate the solid to obtain the fully protected cyclic peptide, which is then cracked in 95% TFA / H2O at room temperature for 2 hours to obtain the initial indole compound.

[0012] In the above scheme: HPLC gradient elution was used to separate and purify the crude peptide.

[0013] In order to further study the relationship between the structure and function of the indole compound of the present invention, an antibacterial experiment was performed to detect the antibacterial ability of the polypeptide, and ampicillin, a commonly used clinical antibiotic, was used as a positive control. The results showed that the bactericidal activity and antibacterial ability of the indole compound were comparable to those of imipenem.

[0014] In order to test the clinical application possibility of indole compounds, it is necessary to test their cytotoxicity in mammalian cells. The antibacterial mechanism of cationic antibacterial cyclic peptides is that their positive charge can electrostatically attract the negatively charged phosphatidylglycerol and cardiolipin in the cell membrane, thereby directly destroying the bacterial cell membrane. Since the cell membrane of eukaryotic cells contains phosphatidylserine and phosphatidylinositol, their negative charge may also bind to antibacterial cyclic peptides to cause cytotoxicity. Therefore, it is very necessary to test the hemolytic toxicity of polypeptides. Experiments have shown that at extremely low concentrations where extremely high antibacterial activity is exerted, the hemolytic toxicity of the indole compounds of the present invention is extremely low.

[0015] The above-mentioned application of anti-multidrug resistant bacteria cyclopeptide in antibacterial treatment.

[0016] The application of the above-mentioned anti-multi-drug resistant bacterial cyclic peptide in resisting Escherichia coli, Staphylococcus aureus and Bacillus subtilis.

[0017] The present invention has the following beneficial effects: The indole derivative provided by the present invention is synthesized using the Fmoc solid-phase chemistry method, which is highly operable and low-cost; this cationic antibacterial cyclic peptide has broad-spectrum killing activity against Escherichia coli, Staphylococcus aureus, and Bacillus subtilis, with the antibacterial activity significantly improved compared to that before cyclization, and is non-toxic to mammalian red blood cells. Even at relatively low concentrations, it has high antibacterial activity. The hemolytic activity of the antibacterial cyclic peptide of the present invention is concentration-dependent, and the hemolytic activity is extremely low at 5 μM. The antibacterial cyclic peptide of the present invention has extremely high antibacterial activity at 5 μM and has extremely high application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 This is the mass spectrum of the indole compound [R3W4V].

[0019] Figure 2 2a, 2b, and 2c represent the antibacterial rates of the indole compound [R3W4V] of the example.

[0020] Figure 3 a, 3b, and 3c represent the antibacterial rates of the linear peptide of the indole compound of the control example.

[0021] Figure 4 The hemolytic activity of the indole compound of Example [R3W4V] is shown. DETAILED DESCRIPTION

[0022] The present invention will be further described below with reference to the accompanying drawings and examples:

[0023] Example 1

[0024] An indole compound has a chemical structural formula I. The indole compound is an anti-multidrug resistant bacterial cyclic peptide containing an amino acid sequence: RRRWWWWV; i.e., Arg-Arg-Arg-Trp-Trp-Trp-Trp-Trp-Val.

[0025] Synthesis begins at the C-terminus of the peptide segment. The first Fmoc-protected amino acid is linked to the dichlororesin 2-CTC resin. The Fmoc residue is then removed and the second amino acid is linked, and all amino acids are linked sequentially. In the second step, the peptide segment is cleaved from the resin to obtain a mixture of peptide segments with all protection removed. In the third step, the fully protected linear peptide is reacted with the condensing agent DIC / Cl-HOBt. After the reaction, water is added to precipitate the solid to obtain the fully protected cyclic peptide. The cyclic peptide is then cleaved by 95% TFA / H2O at room temperature for 2 hours to obtain the initial product. The synthesized product is purified by reverse-phase liquid chromatography (Vydac 218TP1022 column, 2.2*25cm) using an acetonitrile / water system. Mass spectrometry analysis confirms the sequence of the prepared peptide: RRRWWWWV (Arg-Arg-Arg-Trp-Trp-Trp-Trp-Trp-Val).

[0026] The chemical structural formula I finally prepared is:

[0027] .

[0028] The product obtained by the reaction Figure 1 The mass spectrum shown was characterized by Figure 1 It can be seen that the mass spectrum verified the formation of the cyclic peptide.

[0029] Example 2

[0030] In this example, the antibacterial activity of indole compounds was tested. The strains used in the following examples were purchased from the China National Institute for the Control of Biological Products. The antibacterial activity of the indole compounds was assayed using ampicillin as a positive control and an uncyclized linear antimicrobial peptide (RRRWWWWV) synthesized by solid-phase synthesis as a control to evaluate the antibacterial activity of the indole derivatives [R3W4V] of the present invention.

[0031] The antibacterial activity of indole compounds was determined as follows: Bacteria growing in the logarithmic phase were harvested, centrifuged at 8000 rpm for 2 minutes at 4°C, washed three times with saline, and added to fresh LB medium. The OD600 of the bacterial suspension was determined to be between 0.2 and 0.3. Five milliliters of bacterial suspension were added to a test tube, followed by 500 μL of peptide solution or ampicillin solution at varying concentrations, resulting in final antimicrobial cyclic peptide concentrations (nM) of 25, 100, 500, and 5000, respectively, and final antimicrobial peptide concentrations (nM) of 100, 500, 5000, and 30,000, respectively. An equal volume of PBS buffer was used as a growth control. Three replicates were set up for each group and incubated in an incubator at 37°C and 120 rpm for 12 hours. Bacterial growth (OD600 nm) was measured by UV spectrophotometry.

[0032] The inhibition rate was: (growth control group-experimental group) / (growth control group-ampicillin group)*100%.

[0033] from Figure 2 As can be seen from a-2c, the indole compound of the present invention has a very strong antibacterial ability, and has an inhibitory effect on Escherichia coli, Staphylococcus aureus, and Bacillus subtilis, and has a broad-spectrum antibacterial activity; and the antibacterial concentration is low, and it has more excellent applicability.

[0034] from Figure 3 a-3c It can be seen that the uncyclized linear antimicrobial peptide also has antibacterial ability, but compared Figure 2 、 Figure 3 It can be seen that the antibacterial ability of the indole compound of the present invention is much higher than that of the uncyclized linear antibacterial peptide with the same sequence, and the antibacterial ability of the cyclized antibacterial cyclic peptide is greatly improved.

[0035] Example 3

[0036] In this example, the hemolytic activity of indole compounds was tested. This example was used to test the hemolytic rate of indole compounds on mouse red blood cells, using Triton X-100 as a control. Blood samples were collected from Kunming mice.

[0037] The detection steps of the hemolytic activity of indole compounds are as follows: blood is collected from the mouse orbit, centrifuged at 2000 rpm for 5 minutes at 4°C, the supernatant is discarded, the red blood cells are washed three times with physiological saline, and then resuspended into a 6% red blood cell suspension.

[0038] To 100 μl of erythrocyte suspension, add 100 μl of antimicrobial cyclopeptide at different concentrations, giving final antimicrobial cyclopeptide concentrations (μM) of 5, 12.5, 50, 100, and 200 μM. An equal volume of normal saline was used as the negative control, and 0.5% Triton X-100 was used as the positive control. Three parallel groups were set up for each group. The cells were incubated in a 37°C, 120 rpm incubator for 30 minutes. After centrifugation at 2000 rpm for 3 minutes, 150 μL of the supernatant was transferred to a 96-well plate. The absorbance was measured at 540 nm using a microplate reader. The hemolytic activity was calculated as: (experimental group - negative control group) / (positive control group - negative control group) * 100%.

[0039] from Figure 4 It can be seen that the hemolytic activity of the antibacterial cyclic peptide of the present invention is concentration-dependent, and the hemolytic activity is extremely low at 5 μM. Based on the fact that the antibacterial cyclic peptide of the present invention has extremely high antibacterial activity at 5 μM, its application value is extremely high.

[0040] The present invention is not limited to the above embodiments. Those skilled in the art will appreciate that various changes, modifications, substitutions and variations may be made to these embodiments without departing from the principles and purpose of the present invention. The scope of the present invention is defined by the claims and their equivalents.

Claims

1. An indole derivative of formula I, It is characterized in that It has broad-spectrum killing activity against Escherichia coli, Staphylococcus aureus, and Bacillus subtilis; Chemical formula I is: 。 2. A method for synthesizing the indole derivative according to claim 1, It is characterized in that The preparation method is to adopt Fmoc solid phase synthesis method. The following steps are involved: In the first step, the synthesis starts from the C-terminus of the peptide segment. First, the first amino acid with Fmoc protection is linked to the resin, and then the Fmoc is removed and the second amino acid is linked. All amino acids are connected in sequence. In the second step, the connected peptides are cleaved from the resin to obtain a mixture of peptides without all protections; In the third step, the fully protected linear peptide is reacted with a condensing agent, and after the reaction, water is added to precipitate the solid to obtain the fully protected cyclic peptide, which is then cleaved to obtain the initial cyclic peptide product; In the first step, the resin is dichlororesin 2-CTC; The cleavage conditions were 95% TFA / H 2 O was lysed at room temperature for 2 hours.

3. The method for synthesizing the indole derivative according to claim 2, Features: The cyclic peptide was separated and purified by HPLC gradient elution.

4. The method for synthesizing the indole derivative according to claim 2, Features: The condensation agent is DIC / Cl-HOBt.

5. Use of the indole derivative according to claim 1 in the preparation of an antibacterial agent, Features: The antibacterial agents can be used to treat Escherichia coli, Staphylococcus aureus, and Bacillus subtilis.